Prevention of post-ERCP pancreatitis: Pharmacologic solution or patient selection and pancreatic stents?

Gastroenterology

Volumn 124, Issue 7, 2003, Pages 1977-1980

  Freeman, Martin L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; CORTICOSTEROID; DICLOFENAC; GABEXATE; GLUCAGON; GLYCERYL TRINITRATE; HEPARIN; INTERLEUKIN 10; NONIONIC CONTRAST MEDIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; SOMATOSTATIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG INFUSION; EDITORIAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENZYME ACTIVATION; EPIDEMIOLOGICAL DATA; HUMAN; META ANALYSIS; PANCREAS DUCT; PANCREATITIS; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STENT;

EID: 0038281401     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00553-5     Document Type: Editorial

References (20)

1. Murray B, Carter C, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003;124:1786-1791.
2. Testoni PA. Preventing post-ERCP pancreatitis: where are we? J Pancreas 2003;4:22-32.
3. Poon RTP, Fan ST. Antisecretory agents for prevention of post-ERCP pancreatitis: rationale for use and clinical results. J Pancreas 2003;4:33-40.
4. Cavallini G, Frulloni L. Antiproteasic agents in the prevention of post-ERCP pancreatitis: rationale for use and clinical results. J Pancreas 2003;4:75-82.
5. Andriulli A, Caruso N, Quitadamo M, Forlano R, Leandro G, Spirito F, De Maio G. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study. J Pancreas 2003;4:41-48.
6. Demols A, Deviere J. New frontiers in the pharmacological prevention of post-ERCP pancreatitis: the cytokines. J Pancreas 2003;4:49-57.
7. Mariani A. Pharmacological prevention of post-ERCP pancreatitis: which therapy is best? J Pancreas 2003;4:68-74.
8. Freeman ML, Adverse outcomes of ERCP. Gastrointest Endosc 2002;56(suppl 6):S273-S282.
9. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, Moore JP, Fennerty MD, Ryan ME, Shaw MJ, Lande JD, Pheley AM. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-918.
10. Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ, Overby CS, Aas J, Ryan ME, Bochna GS, Shaw MJ, Snady HW, Erickson RV, Moore JP, Roel JP. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. Gastrointest Endosc 2001;54:425-434.
11. Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F, DeBernardin M, Ederle A, Fina P, Fratton A. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998;48:1-10.
12. Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M, Minoli G, Crosta C, Comin U, Fertitta A, Prada A, Passoni GR, Testoni PA. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001;96:417- 423.
13. Friedland S, Soetikno RM, Vandervoort J, Montes H, Tham T, Carr-Locke DL. Bedside scoring system to predict the risk of developing pancreatitis following ERCP. Endoscopy 2002; 34:483-488.
14. Trap P, Adamsen S, Hart-Hansen O, Henriksen M. Severe and fatal complications after therapeutic ERCP: a prospective series of claims to insurance covering public hospitals. Endoscopy 1999;31:125-130.
15. Tarnasky P, Palesch Y, Cunningham J, Maulsin P, Cotton P, Hawes RH. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998;115:1518-1524.
16. Fazel A, Quadri A, Catalano MF, Meyerson SM, Geenen JE. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003;57:291-294.
17. Tarnasky P. Mechanical prevention of post-ERCP pancreatitis by pancreatic stents: results, techniques, and indications. J Pancreas 2003;4:58-67.
18. Fogel EL, Eversman D, Jamidar P, Sherman S, Lehman GA. Sphincter of Oddi dysfunction: pancreatobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis rate than biliary sphincterotomy alone. Endoscopy 2002; 34:280-285.
19. Kozarek RA. Pancreatic stents can induce ductal changes consistent with chronic pancreatitis. Gastrointest Endosc 1990;36: 93-95.
20. Cotton PB, Lehman G, Vennes JA, Geenen JE, Russell RCG, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-391.